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Prenatal androgen excess is considered one of the main causes of the development of polycystic 
ovary syndrome. In this study, we investigated the effect of prenatal hyperandrogenization (PH) 
on the physiology of the adult uterine tissue using a murine model of fetal programming caused 
by androgen excess in adult female rats. Pregnant rats were hyperandrogenized with 
testosterone and female offspring were studied when adult. Our results showed that PH leads to 
hyperglycemia and hyperinsulinemia. Consequently, PH developed insulin resistance and a 
systemic inflammatory state reflected by increased C-reactive protein. In the uterine tissue, 
levels of PPAR gamma—an important metabolic sensor in the endometrium—were found to be 
impaired. Moreover, PH induced a pro-inflammatory and an unbalanced oxidative state in the 
uterus reflected by increased COX-2, lipid peroxidation, and NF-kB. In summary, our results 
revealed that PH leads to a compromised metabolic state likely consequence of fetal 
reprogramming.  
 




Polycystic ovary syndrome (PCOS) is a multifactorial endocrinopathy among women at 
reproductive age and the major cause of anovulatory infertility (Joham et al., 2015); its 
incidence is as high as 5-15% (Li et al., 2018). PCOS diagnosis comprises combinations of 
female hyperandrogenism, oligo- or anovulation, and polycystic ovaries. The etiology of PCOS 
remains unknown; however, current hypotheses propose that prenatal androgen excess during 
intrauterine life could lead to the development of the syndrome. It is important to point out that 
while PCOS patients present a high rate of spontaneous miscarriage and are often infertile 
mainly due to ovulation failure, if ovulation is restored, pregnancy rates still remain low 










could be attributed to a failure in the endometrial receptivity (Lopes et al., 2011) necessary for 
successful embryo implantation (Amjadi et al., 2018; Matsuzaki et al., 2017). 
It is apparent that a link between PCOS and oxidative stress exists, yet whether oxidative stress 
is a cause or a consequence in the development of this pathology is still unclear (Lee et al., 
2010; Macut et al., 2013). Oxidative stress is the result of an imbalance between the production 
of reactive oxygen species (ROS) and their inactivation by antioxidant mechanisms. 
Hyperinsulinemia, a very common feature in PCOS, induces an inflammatory response as 
evidenced by increased ROS-associated oxidative stress and activation of NF-κB. When ROS 
induces oxidative stress, NF-κB translocates to the nucleus to promote the transcription of 
TNFα and IL-6 (Barnes and Karin, 1997). Additionally, chronic inflammation plays a key role 
in the pathogenesis of PCOS (González, 2012; Sirmans et al., 2012) and is reflected by the 
presence of  C-reactive protein (CRP) in circulation (Kelly et al., 2001). An imbalance among 
pro- and anti-inflammatory factors could be implicated in impaired endometrial function and 
infertility associated with PCOS (Amjadi et al., 2018). Chronic inflammation and oxidative 
stress are closely related. Therefore, it has been proposed a vicious cycle, whereby inflammation 
induces generation of ROS, while oxidative stress promotes and aggravates inflammation 
(Duleba and Dokras, 2012). Both factors could induce tissue damage and affect multiple 
physiological processes such as ovulation, fertilization, implantation, embryo development and 
pregnancy by altering the function of the ovaries and the uterus (Agarwal et al., 2005). 
Peroxisome proliferator-activated receptor gamma (PPARg) has been identified as playing a 
crucial role in the control of fertility. This receptor is required for the attachment of embryos to 
the endometrium and for the development and function of the placenta. PPARg also controls the 
immune response through its ability to inhibit the expression of inflammatory cytokines and to 
direct the differentiation of immune cells toward anti-inflammatory phenotypes (Minge et al., 
2006). Some reports suggest that PPARg regulates inflammatory processes in the endometrium. 
Moreover, it has been reported that PPARg modulates cyclooxygenase (COX)-2 expression, the 










Prenatal hyperandrogenization (PH) in females leads to the appearance of a PCOS phenotype in 
adulthood (Abbott et al., 2008; Motta, 2010; Padmanabhan and Veiga-Lopez, 2013; van Houten 
and Visser, 2014). These prenatally induced-PCOS animal models are usually permanent, due to 
specific developmental disturbances during the maturation and differentiation of the organs, 
leading to alterations of their structures and functions (Abbott et al., 2007). Our laboratory has 
been working in a rat model of PCOS that recreates the endocrine, ovarian, and uterine 
disturbances of the pathology, thus allowing for the exploration of reproductive and metabolic 
disorders (Abruzzese et al., 2016; Ferreira et al., 2020; Heber et al., 2019). Using this model, the 
present work aimed to study the systemic glucose/insulin homeostasis, the oxidant/antioxidant 
balance, the inflammatory status, and the expression of PPARg in the uterine tissue of 
prenatally androgenized rats when adult.  
 
2. Materials and Methods 
2.1 Experimental animal model and ethics statement 
Virgin female rats of the Sprague-Dawley strain were mated with fertile males of the same 
strain. Three females and one male were housed together under controlled conditions of light 
(12 h light: 12 h dark) and temperature (23–25°C). Animals received food (Cooperación SRL, 
Argentina) and water ad libitum. Day 0 of pregnancy was defined as the day in which 
spermatozoa were observed in the vaginal lavages. Between days 16 and 19 of pregnancy, rats 
were hyperandrogenized as previously described (Abruzzese et al., 2016; Heber et al., 2019). 
Briefly, pregnant rats (N=15) received subcutaneous injections of 1 mg of free testosterone 
(Sigma Chemical Co. St. Louis, MO, USA) dissolved in 100 µl of sesame oil (Sigma) on days 
16, 17, 18, and 19 of pregnancy, whereas the control group (N=15) received the same number of 
injections containing only 100 µl of sesame oil used as vehicle. The dose of testosterone 
administered resulted in circulating testosterone levels similar to those of male rats (Wolf et al., 
2002). All the procedures involving animals were conducted in accordance with the 1996 










Técnicas (CONICET). The present study was approved by the Ethics Committee of the Facultad 
de Medicina, Universidad de Buenos Aires, Argentina. 
The treatments described did not modify the spontaneous term labor, the female-to-male 
offspring ratio, or the number of pups per litter. Under the conditions of our animal facility, 
spontaneous term labor occurs on day 22 of pregnancy (Abruzzese et al., 2016). Pups were 
culled from litters to equalize group sizes (ten pups/mother). Female pups were separated from 
males at 21 days of age, and randomly assigned to each assay, which was carried out with the 
same number of animals from each randomly selected littermate. The group of female offspring 
prenatally treated with testosterone was designated as the prenatally hyperandrogenized group 
or PH group, whereas the offspring of animals receiving vehicle composed the control or C 
group. The age at vaginal opening did not differ between C and PH groups. These animals 
showed their vaginal opening around day 33 of life (Abruzzese et al., 2019). Estrous cycles 
from C and PH groups were monitored daily by vaginal smears beginning at 70 days of age 
and until decapitation after 90 days. The results of estrous cycle study let us define three 
experimental groups. The control group (C) had normal cycles (4-6 days), whereas those 
animals prenatally exposed to androgens showed one of the two following phenotypes: 
ovulatory phenotype (PH ov) displaying prolonged cycles lasting 7 days or more (going 
through all stages of the estrous cycle –in order or not-), or anovulatory phenotype (PH 
anov) with no cycles at all (this group remained arrested at diestrus stage) (Abruzzese et al., 
2016; Karim et al., 2003). PH rats displayed a hyperandrogenic state during early puberty and 
adulthood as evidenced by higher levels of testosterone in the PH groups than in the control 
group (Abruzzese et al., 2016; Heber et al., 2019). At 90 days (day of euthanasia) the entire 
PH anov group remained in diestrus; for that reason, and to allow comparison among groups, all 
animals were killed on the first diestrus after 90 days of age. Female offspring from each 
experimental set of animals were weighed, anesthetized with carbon dioxide, and killed by 
decapitation. Trunk blood was collected, and serum was separated and kept at −80°C for further 
studies. One horn of the uterus was extracted and conserved at -80°C for PCR and Western blot 










h at 4°C and used for histology purposes. Following paraffin embedding and sectioning (5μm), 
two sections per sample were stained with hematoxylin and eosin (H&E), whereas subsequent 
sections were used for immunohistochemical studies. 
 
2.2 Body weight and metabolic parameters 
The body weight of all the animals of all the groups was assessed at 21, 28, 38, 45, 60, 75, and 
90 days of age. Fasting blood glucose was determined by using Accu-Chek test strips (Roche, 
Basel, Switzerland) for visual determination in the range of 20–800 mg/100 ml (1–44 mmol/l) 
(N=10 per group). Fasting insulin levels were measured by an ELISA kit following the 
manufacturer’s instructions (Insulin Human ELISA Kit; Abcam, Cambridge, United Kingdom) 
(N=10 per group). The intra- and interassay coefficient of variation values for insulin were 10% 
and 12% respectively. Serum glucose levels were expressed as mg/dl and insulin levels as 
μIU/ml. The homeostatic model assessment for insulin resistance (HOMA-IR) was calculated 
according to the formula: fasting insulin (μIU/ml) x fasting glucose (mg/dl)/405 (Matthews et 
al., 1985). 
 
2.3 Western blot and quantitative analysis 
Uterine tissues were lysed and prepared for protein extraction (N=8/group). The lysis solution 
contained 50 mM Tris-HCl (pH 7.4), 150 mM NaCl (Sigma), 0.5% NP-40 (Sigma), 1 mM 
PMSF (Sigma), 1 μg/ml pepstatin (Sigma), 2 g/ml aprotinin (Sigma), 2 g/ml leupeptin 
(Sigma), 1 mM DTT (Promega, Madison, WI, USA), 1 mM sodium orthovanadate (Sigma), and 
50 mM sodium fluoride (Sigma). This buffer was added to 50 mg of uterine tissue for 30 min at 
4°C and subjected to homogenization using a pestle mixer. Uterine lysates were then 
centrifuged at 14,000 g for 20 min at 4°C, and the supernatant was considered the whole cell 
extract, which was assayed for protein content using the bicinchoninic acid method (BCA; 
Pierce, Rockford, IL, USA). After boiling for 5 min at 95°C, equal amounts of proteins per 










GmbH, Munchen, Germany) and transferred onto low fluorescence PVDF membranes (Bio-
Rad) for 7 min using the Trans-Blot Turbo Blotting System (Bio-Rad) following the 
manufacturer´s instructions. The blots were blocked for 1 hour in 5% (w/v) non-fat dry milk in 
Tris-buffered saline containing 0.1% (v/v) Tween 20 (TBST). After blocking, the membranes 
were probed overnight at 4°C with the primary antibodies in TBST containing 5% (w/v) non-
fat dry milk or 5% (w/v) bovine serum albumin (in the case of phosphorylated proteins). The 
blots were washed 5 × 5 min in TBST and incubated with HRP-conjugated secondary antibody 
for 1 hour at room temperature. Blots were washed and developed by chemiluminescence 
(Clarity Western ECL Substrates, Bio-Rad). Ultraviolet activation of the TGX stain-free gel 
on a ChemiDoc MP Imaging System (Bio-Rad) was used to control for proper loading. Band 
densitometry was performed using Image Laboratory Software (Version 6.0, Bio-Rad). When 
quantified, the intensity of each protein band was normalized to the total protein in individual 
samples to adjust for unequal loading and transfer (Taylor et al., 2013; Taylor and Posch, 2014; 
Zhang et al., 2017). The identity of the antibodies used for Western blotting are detailed in 
Table 1.  
 









Cyclooxygenase-2 Abcam Ab15191 1:2000 1:200  
GSK-3β Cell Signaling 12456 1:1000  
Phospho-GSK-3β Cell Signaling 9336 1:1000  
NF-κB Cell Signaling 8242 1:1000 
 PPAR gamma Abcam Ab209350 1:1000 1:100   
Goat Anti-Rabbit IgG -HRP Conj. Bio-Rad 1706515 1:10000   
Goat Anti-Mouse IgG – HRP Conj. Jackson 115-035-003 1:8000   
 
Table 1. List of antibodies and dilution used for western blotting (WB) and 
immunohistochemistry (IHC) purposes. 
 










Paraffin sections (N=5/group) were deparaffinized and rehydrated through a graded alcohol 
series followed by antigen retrieval in 10 mM sodium citrate buffer, pH 6.0 for 40 min with 
steaming (IHC WORLD, Woodstock, MD, USA). Slides were treated with 0.5% Triton X-100 to 
allow permeabilization. Thereafter, slides were blocked with 5% normal horse serum (NHS) 
(Vector Labs, Burlingame, CA, USA) for 20 minutes at room temperature. The primary 
antibodies (see list and concentrations on Table 1) were diluted in NHS and incubated overnight 
at 4°C or for 1 hour at room temperature in a humidified chamber. Thereafter, the sections were 
incubated with 3% hydrogen peroxide to remove endogenous peroxidase activity. After being 
washed with phosphate-buffered saline containing 0.1% (v/v) Tween 20 (PBST), and 
phosphate-buffered saline (PBS), the samples were incubated for 30 minutes at room 
temperature with the secondary antibodies identified in Table 1. Sections were visualized with 
3,3-diaminobenzidine tetrahydrochloride (Vector Labs). Negative controls were performed, 
following the same protocol, except that the tissue was not incubated with a primary antibody. 
Positive tissue controls were performed using cancer cell lines that are known to express the 
proteins of interest (data not shown). Slides were viewed on a microscope (Amscope MU1000) 
and photomicrographed using AmScope Software 3.7 (United Scope LLC, Irvine, CA, USA) 
 
2.5 Quantification of mRNA levels by real-time PCR 
We assessed the mRNA expression of PPARg, COX-2, NcOR, Cu-SOD, TNFa, IL-10 and NF-
κB. All mRNA levels were evaluated by real-time PCR analysis (N=6/group). Briefly, total 
mRNA from uterine tissue was extracted using RNAzol RT (MRC gene, Molecular Research 
Center, Cincinnati, OH, USA), following the manufacturer´s instructions. cDNA was 
synthesized from 1 μg mRNA using random primer hexamers (Invitrogen-Life Technologies, 
Buenos Aires, Argentina). Real-time PCR analysis was performed from this cDNA (2.5μL) in 
10 μl reaction buffer containing 20 mM dNTPs mix, GoTaq Polymerase (Promega), Eva Green 
20x (Biotium Hayward, CA, USA), and gene-specific primers in a total volume of 12.5 μl. The 
qPCR conditions started with a denaturation step at 95°C for 5 min and followed by up to 50 










primer extension (72 °C). The amplified products were quantified by fluorescence using the 
Rotor-Gene 6000 (Corbett Life Science, Sydney, Australia), and mRNA abundance was 
normalized to the amount of 60s Ribosomal protein L32 (L32). L32 was validated as a reference 
gene as the variance between treatments did not differ. Gene expression was quantified using 
the 2
–ΔΔCt 
method (Livak and Schmittgen, 2001). Results are expressed as a fold value of the 
controls. 
 
Table 2.  Primers used in the study 
 
Gene Primer sequences 
Temperature of 
melting (°C) 
L32 F TGGTCCACAATGTCAAGG 
58 
L32 R CAAAACAGGCACACAAGC 
Ncor F TATCGGAGCCATCTTCCCAC 
60 
Ncor R ACTTGGGTATCCTGGGGTTG 
Cusod F GTCGTCTCCTTGCTTTTTGC 
62 
Cusod R TGCTCGCCTTCAGTTAATCC 
Tnfα F GATCGGTCCCAACAAGGAGG 
62 
Tnfα R CTTGGTGGTTTGCTACGACG 
Il10 F TGAAAAATTGAACCACCCGGC 
62 
Il10 R CCAAGGAGTTGCTCCCGTTAG 
Nf-κb F GAAGAGGATGTGGGGTTTCA 
62 
Nf-κb R CTGAGCATGAAGGTGGATGA 
Pparg F TTTTCAAGGGTGCCAGTTTC 
60 
Pparg R GAGGCCAGCATGGTGTAGAT 
Cox-2 F ATCCTGCCAGCCAGCTCCACCG 
62 
Cox-2 R TGGTCAAATCCTGTGCTCATACAT 
 
Table 2. List of primers used in the real-time PCR. F, forward sequence; R, reverse sequence. 
 
2.6 Oxidative stress-related parameters 
2.6.1 Lipid peroxidation 
The amount of malondialdehyde (MDA) formed from the breakdown of polyunsaturated fatty 
acids may be taken as an index of peroxidation reaction. The method used in the present study 










peroxidation that reacts with trichloracetic acid–thiobarbituric acid–HCl (15% (w/v); 0.375% 
(w/v) and 0.25M, respectively), yielding a red compound that absorbs at 535 nm. Homogenates 
of uterine tissue (N=15/group) were treated with trichloroacetic acid–thiobarbituric acid–HCl 
and heated for 15 min in a boiling water bath. After cooling, the flocculent precipitate was 
removed by centrifugation at 1000 g for 10 min. The absorbance of samples was determined at 
535 nm. The content of thiobarbituric acid reactants was expressed as nM MDA formed/mg 
protein. 
2.6.2 Glutathione (GSH) content 
The antioxidant metabolite GSH was quantified as previously described (Elia, 2006). The 
reduced form of GSH comprises the bulk of cellular protein sulfhydryl groups. Thus, 
measurement of acid soluble thiol is used to estimate the GSH content in tissue extracts. Briefly, 
one uterus per point was homogenized in homogenization buffer (EDTA (1 mM), KCl (150 
mM), beta-mercaptoethanol (1 mM), trizma base (20 mM), and sacarose (500 mM), pH=7.6), 
and centrifuged at 800 g for 10 minutes at 4°C (N=15/group). Then, supernatants (50 μl/point) 
were incubated with 800 μl of 1.5 M Tris buffer (pH 7.4) containing 50 μl of 5.10
-3
 M NADPH 
and 6 IU of GSH reductase. The reaction involves the enzymatic reduction of the oxidized form 
(GSSG) to GSH. When Ellman’s reagent (a sulfhydryl reagent 5,5-dithiobis-2 nitrobenzoic acid 
(Sigma) is added to the incubation medium, the chromophoric product resulting from this 
reaction develops a molar absorption at 412 nm that is linear beyond 6 min; thereafter the 
reaction remains constant. Results are expressed as μM GSH/mg protein. 
 
2.7 Serum C-reactive protein levels determination 
Quantitative determination of serum C-reactive protein (CRP) was analyzed using an 
immunoturbidimetric method (#1683267, Wiener Lab, Argentina) following the manufacturer’s 
instructions (N=15 per group). The CRP reacts with the specific antibody producing insoluble 
immune complexes. The turbidity caused by these immune complexes is proportional to the 










340 nm at 37°C. The intra- and interassay coefficient of variation values were 2.4% and 6.0%, 
respectively. 
 
2.8 Statistical analysis 
Statistical analyses were performed to test the number of samples needed for each experiment 
using Infostat Software (Di Rienzo et al., 2011). The same software was used to test the 
normality of data (Shapiro-Wilks test) and homoscedasticity (Levene’s test). Results are 
presented as the means ± S.E.M. Statistical analyses were performed using GraphPad Instat® 
software (GraphPad Software, San Diego, CA, USA). For normally distributed data, differences 
between groups were analyzed by one-way ANOVA followed by Tukey’s multiple 
comparison test.  
 
3. Results 
3.1 Prenatal androgen excess induces insulin resistance without altering uterine weight 
Insulin resistance homeostasis and growth curve were evaluated to determine, respectively, if 
prenatal androgen excess impairs glucose/insulin homeostasis and gain weight during 
adulthood. Results showed that basal glucose levels were significantly increased in a 
phenotype dependent manner in the PH groups (Fig.1 A). Moreover, insulin levels were 
increased in both PH groups with respect to the control group (Fig.1 B). The homeostatic 
model of assessment for insulin resistance index (HOMA-IR) was increased in the PH groups 
if compared with the control group (Fig.1 C). Prenatal hyperandrogenization did not affect 
the body weight from prepubertal to adult age evaluated through a weight curve during 90 
days (Fig.1 D). Moreover, as a measurement of the relation between uterine growth and body 
weight, the ratio between these factors was analyzed, and showed no differences between 











Figure 1. Effects of prenatal hyperandrogenization on body growth curve and metabolic 
status. Metabolic features evaluated in the female offspring of prenatally hyperandrogenized 
(PH) and control (C) groups. Basal glucose levels (A), basal insulin levels (B) and HOMA-IR 
index (C) (N = 10/group); the curve represents the mean growth rates of the C and PH groups 
(D); uterine weight: body weight ratio (E). Each column represents the mean ± S.E.M. 
Different letters represent statistical significance among the groups, p˂0.05. 
 
3.2 Prenatal androgen excess alters the expression of PPARg in the uterine tissue 
Due to its important role in reproduction, we evaluated the gene and protein expression of 
PPARg in the uterine tissue. Immunohistochemistry showed that the PPARg expression is 
confined to the glandular (Fig.2 A-C) and luminal epithelium (Fig.2 D-F) in all the groups 
studied. Although protein levels of PPARg showed no differences among the groups (Fig.2 G), 
a decrease in gene expression of PPARg was found in the PH anov group (Fig.2 H, J). 
Moreover, the nuclear co-repressor NcOR, which represses PPARg, was found to be decreased 











Figure 2. Effects of prenatal hyperandrogenization on PPARg expression. PPARg uterine 
expression was evaluated in the prenatally hyperandrogenized (PH) and control (C) groups. 
Immunohistochemical detection of PPARg in paraffin embedded uterine tissue sections of rats 
in diestrus, from control (A, D), PH ov (B, E), or PH anov (C, F) groups. Scale bars are 
indicated in the photomicrographs and represents 50 μm (A-F). As a negative control, the 
primary antibody was omitted (insert in A, D) (N = 5/group). Results of Western blotting for 
PPARg (G, J); equal amounts of uterine proteins were loaded in each lane (N = 8/group), 
mRNA expression of PPARg (H) and NcOR (I) both relative to L32 (N = 6/group). Each 
column represents the mean ± S.E.M. Different letters represent statistical significance among 











3.3 Prenatal androgen excess induces a pro-inflammatory state in the uterine tissue 
We studied the expression of pro-inflammatory (COX-2, TNFα, CRP) and anti-inflammatory 
markers (IL-10), and of NF-κB as a regulator of the expression of inflammatory genes.  Positive 
COX-2 staining was found mainly in the glandular and luminal epithelium of the uterine tissue 
(Fig.3 A-F). When assessed by western blotting, COX-2 protein expression was found to be 
increased in the PH groups (Fig.3 G, I) when compared to the C group. Moreover, mRNA levels 
of COX-2 were increased in a phenotype dependent manner in both PH groups (Fig.3 H). 
Increased expression of NF-κB protein was found only in the PH ov group (Fig.4 A, B); 
however, no differences were found in the NF-κB mRNA levels among all groups studied 
(Fig.4 C). Furthermore, mRNA levels of TNFα were analyzed but no differences were found 
between groups (Fig.4 D). On the other hand, as an anti-inflammatory marker, we evaluated the 
mRNA expression of IL-10, and we found that only the PH ov group presents significantly 
increased IL-10 mRNA levels (Fig.4 E). As a systemic inflammatory marker, serum levels of 












Figure 3. Effects of prenatal hyperandrogenization on COX-2 expression. COX-2 was 
evaluated in the uterus of prenatally hyperandrogenized (PH) and control (C) groups. 
Immunohistochemical detection of COX-2 in paraffin embedded uterine tissue sections of rats 
in diestrus, from control (A, D), PH ov (B, E), or PH anov (C, F) groups. Scale bars are 
indicated in the photomicrographs and represents 50 μm (A-F). As a negative control, the 
primary antibody was omitted (insert in A, D) (N = 5/group). Results of Western blotting for 
COX-2 (G, I), equal amounts of uterine proteins were loaded in each lane (N = 8/group); 
mRNA expression of COX-2 (H) relative to L32 (N = 6/group). Each column represents the 












Figure 4. Effects of prenatal hyperandrogenization on inflammation markers. 
Inflammation markers were evaluated in the uterus of prenatally hyperandrogenized (PH) and 
control (C) groups. Results of Western blotting for NF-κB (A, B) [equal amounts of uterine 
proteins were loaded in each lane (N = 8/group)], and mRNA expression of NF-κB (C) were 
studied; mRNA expression of TNFα (D) relative to L32; mRNA expression of IL-10 (E) relative 










column represents the mean ± S.E.M. Different letters represent statistical significance among 
the groups, p˂0.05. 
 
3.4 Prenatal androgen excess creates an unbalanced oxidative status 
The oxidant–antioxidant balance in the uterine tissue was evaluated. The lipid peroxidation 
index was assessed by using the thiobarbituric acid method (TBARs) through the evaluation of 
malondialdehyde (MDA); results revealed an increased lipid peroxidation index in the PH anov 
group (Fig. 5A).  Whereas TBARs showed a tendency to increase also in the PH ov group, such 
increase was not statistically significant (Fig.5 A). Additionally, the content of the antioxidant 
glutathione was found increased in the PH anov group (Fig.5 B). On the other hand, both PH 
groups showed decreased levels of the mRNA encoding for Cu-SOD, another antioxidant 
enzyme (Zuo et al., 2016) (Fig.5 C). 
 
Figure 5. Effects of prenatal hyperandrogenization on uterine oxidant/antioxidant 
balance. The oxidant–antioxidant balance in the uterine tissue was evaluated in the prenatally 










the thiobarbituric acid method (TBARs) through evaluation of malondialdehyde (MDA) (A) and 
the content of the antioxidant glutathione (N = 15/group) (B). mRNA expression of Cu-SOD 
(C) relative to L32 (N = 6/group). Each column represents the mean + S.E.M. Different letters 
represent statistical significance among the groups, p˂0.05. 
 
3.5 Prenatal androgen excess induces GSK-3β phosphorylation in the uterine tissue 
GSK-3β has numerous functions in the cells; the most important are related with glucose 
homeostasis and NF-κB signaling (Lee and Kim, 2007). Western blot results revealed that the 
expression of the total form of GSK-3β (Fig.6 A, C) and the phosphorylated form of GSK-3β 
on Ser 9 (Fig.6 B, C) were increased in both PH groups when compared to the controls.  
 
Figure 6.  Effects of prenatal hyperandrogenization on GSK-3β expression. GSK-3β total 
and phosphorylated form were evaluated in the prenatally hyperandrogenized (PH) and control 
(C) groups. Results of Western blotting for GSK-3β (A, C) and phospho-GSK-3β (Ser9) (B, C); 
equal amounts of uterine proteins were loaded in each lane (N = 8/group). Each column 














In this study, we used our rat model that mimics PCOS features through prenatal testosterone 
exposure. Female offspring showed two phenotypes, ovulatory and anovulatory confirming 
our previous reports (Abruzzese et al., 2019; Ferreira et al., 2020). 
Oxidative stress and inflammation have been related to the pathogenesis of PCOS (Escobar-
Morreale et al., 2011; Zhao et al., 2015). Moreover, it has been described that PCOS patients 
present a pro-inflammatory state that could be aggravated by the presence of insulin resistance 
(Palomba et al., 2014). Furthermore, as PPARg was reported to be a modulator of proliferation, 
inflammation, and cell differentiation processes in the uterus (Brooks et al., 2015; Nickkho-
Amiry et al., 2012), it might play an important role in the reproductive function. Therefore, 
considering PPARg as an energy-metabolic sensor, it could be used as a good indicator of the 
uterine inflammatory and redox state, particularly during pregnancy (Schaiff et al., 2006). Under 
physiological conditions, the PPAR system regulates uterine function; consequently, we aimed 
to evaluate how altered PPARg is in the uterus under the pathological condition of our PCOS 
model. Results show altered expressions of PPARg and NcOR in the PH anov phenotype, 
suggesting a possible dysregulation of the downstream pathways that PPARg control. The 
results are in accordance with previous reports from our laboratory in which prenatal 
hyperandrogenization was induced with a higher dose of testosterone (Ferreira et al., 2019). 
However, previously in our laboratory, opposite results were found at the level of the ovaries 
(Amalfi et al., 2012). This discrepancy could be explained due to the different amount of 
testosterone used, or because of organ specificity. Furthermore, other authors have reported a 
decrease in PPARg expression in endometrial cancer and in other tumor cell types (Knapp et al., 
2012). 
PPARg regulates the expression and activity of COX-2 (Sheldrick et al., 2007). This can be 
explained considering the existence of a direct interaction between PPARs and prostaglandins 
due to the presence of a PPAR response element in the promoter of the COX-2 gene (Knopfová 
and šMarda, 2010; Meade et al., 1999). In the present work, our results revealed that PH induces 










of COX-2. Previously, we demonstrated that under this model of prenatal androgen excess, the 
luminal epithelium of the endometrium becomes hyperplastic (Ferreira et al., 2020). Taken 
together, these results suggest that the deregulation of tissue homeostasis triggers a pro-
inflammatory state in the luminal epithelium of the uterine tissue. Moreover, alterations in the 
expression of COX-2 and PPARg have been found in endometriosis and in different types of 
cancer (Adelizzi, 1999; Sobolewski et al., 2010), but have not yet been elucidated in the 
endometrium of animals exposed to prenatal androgen excess. Several studies have reported an 
inverse correlation between PPARg and COX-2 levels in different types of cancers (Badawi and 
Badr, 2003; Gustafsson et al., 2007; Knopfová and šMarda, 2010; Konstantinopoulos et al., 
2007); we found a similar trend in the uterine tissue of the PH anov group. This is interesting as 
the weaker the expression of PPARg, the higher the level of COX-2 / PGE-2, which could favor 
tumor development and progression (Badawi and Badr, 2003; Sasaki et al., 2002). 
Our results also showed that the PH anov group presents an elevated systemic inflammatory 
status as depicted by elevated CRP, which is considered a biomarker of low-grade chronic 
inflammation in women with PCOS (Repaci et al., 2011). Our data are in agreement with other 
investigations that have reported significantly increased CRP levels in patients with PCOS 
(Bannigida et al., 2018; Blumenfeld, 2019; Boulman et al., 2004). 
Our animal model of prenatal androgen excess let us recreate numerous PCOS features, among 
them oxidative stress, which is considered a contributing factor in triggering the condition. We 
also found that PH increased lipid peroxidation in the anovulatory phenotype; as a response, the 
antioxidant mediator GSH increased, suggesting a compensatory mechanism against the hyper-
oxidative state. In contrast, another protective mechanism against oxidative stress mediated by 
Cu-SOD was depleted in the PH groups. As a summary, studies indicate that oxidative stress is 
increased in PCOS patients when compared to patients without PCOS (Escobar-Morreale et al., 
2011; Murri et al., 2013). It has also been shown that oxidative stress significantly correlates 
with obesity, hyperandrogenism, insulin resistance, and chronic inflammation (Lu et al., 2018).  
Insulin resistance induces oxidative stress because hyperglycemia and high levels of free fatty 










insulin resistance found in PH groups could explain the pro-oxidant status found in these 
animals. Moreover, other authors have demonstrated that ROS and pro-inflammatory factors, 
produced under oxidative stress, could induce insulin resistance mainly through the PI3K-Akt 
pathway by activating NF-κB and JUNK, likely via GSK-3β (Kamata et al., 2005; Keane et al., 
2015). In agreement, PH groups present increased Ser 9 phosphorylation of GSK-3β, 
suggesting an activation of AKT (Heber et al., 2019).  
In the current work, we found elevated levels of glucose and insulin in the circulation of the 
PH groups. Hyperinsulinemia together with oxidative stress may promote cell proliferation and 
genetic instability due to DNA damage leading to malignant transformation and the 
development of cancer in a context of PCOS (Papaioannou and Tzafettas, 2010). Also, it has 
been demonstrated that oxidative stress is associated with metabolic disorders that could 
interfere in the physiology of PCOS, and are potential inducers of the characteristic associated 
features of the pathology (Di˙ncer et al., 2005; González et al., 2009). Moreover, it was reported 
in patients with PCOS that oxidative stress and inflammation markers correlate positively with 
androgen levels (González et al., 2005; Yang et al., 2011; Yilmaz et al., 2005). 
It is important to point out that mRNAs does not always directly reflects what happen at the 
protein level.  Modifications to mRNA could affect their stability and its levels, affecting their 
translational efficiency. Moreover, miRNAs function to control translation efficiencies, which 
may be why some RNAs may not be translated. In contrast, others are translated more 
efficiently. Another critical factor is the protein stability, which also could be affected by a post-
translational modification. These issues could explain in some part the different results between 
mRNA and protein levels obtained in the present study. 
In conclusion, this study demonstrated that prenatal hyperandrogenization in an animal model 
which mimics metabolic, ovarian, and uterine features of PCOS. We recognize the limitations 
of animal models; however, the findings presented in this study could help to elucidate the 
extent of prenatal hyperandrogenization misbalances, especially in the uterus, which is a very 
relevant reproductive organ. Prenatal exposure to testosterone lead to the development of 










known features that contribute to the pathogenesis of PCOS and may likely increase the risk of 
malignant transformation in the uterus. 
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• Prenatal hyperandrogenization leads to a fetal programming effect in the 
rat uterus. 
• PPAR system and its regulators were altered in the uterine tissue of adult 
rats. 
• A pro-inflammatory environment was created in the uterine tissue of adult 
rats. 
• A misbalanced oxidant/antioxidant state was established in the uterine 
tissue. 
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